Biogen partner Eisai shares jump after FDA approves Alzheimer’s drug Leqembi
The Japanese company surged almost 10% in Tokyo trading following initial US clearance of Leqembi (lecanemab) for the treatment of Alzheimer’s disease.
By Kanoko Matsuyama, bloomberg
Eisai Co. surged the most in more than three months after winning initial US regulatory clearance for lecanemab, the first treatment seen to slow the advance of brain-wasting Alzheimer’s disease.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Investigation questions FDA approval of Aduhelm
For subscribers
